Last data update: May 20, 2024. (Total: 46824 publications since 2009)
Records 1-8 (of 8 Records) |
Query Trace: Bedrosian S[original query] |
---|
CDC's guiding principles to promote an equity-centered approach to public health communication
Calanan RM , Bonds ME , Bedrosian SR , Laird SK , Satter D , Penman-Aguilar A . Prev Chronic Dis 2023 20 E57 A public health practitioner's mission is to protect and promote the health of all people in all communities. Components of being successful in that mission include understanding who is at risk of negative outcomes, identifying effective actions to promote and protect health, and communicating information accordingly. Information must be scientifically rigorous, provide appropriate contextualizing information, and refer to and visually represent people through words and images in respectful ways. Public health communication objectives include that the audience accepts, understands, and acts on the information to protect and promote health. This article describes the impetus for, development of, and public health applications and implications of principles to guide communication efforts. CDC's Health Equity Guiding Principles for Inclusive Communication is a web-based resource published in August 2021 that offers - but does not mandate - guidance and recommendations for public health practice. The resource can help public health practitioners and their partners consider social inequities and diversity, think more inclusively about the people they serve, and adapt to the cultural, linguistic, environmental, and historical situation of each population or audience of focus. Users are encouraged to have conversations about the Guiding Principles as they plan and develop communication products and strategies in collaboration with communities and partners and build a shared vocabulary consistent with how communities and groups of focus see and understand themselves, because words matter. As the public health field renews its focus on shifting the paradigm toward equity, a language and narrative shift is a vital intervention. |
Determinants and characterization of exposure to phthalates, DEHTP and DINCH among pregnant women in the PROTECT birth cohort in Puerto Rico
Rodríguez-Carmona Y , Ashrap P , Calafat AM , Ye X , Rosario Z , Bedrosian LD , Huerta-Montanez G , Vélez-Vega CM , Alshawabkeh A , Cordero JF , Meeker JD , Watkins D . J Expo Sci Environ Epidemiol 2020 30 (1) 56-69 BACKGROUND: As a result of evidence suggesting phthalate toxicity, their use has decreased in recent years. However, new phthalates and non-phthalate replacements have emerged in their place, with unknown potential impacts on health. METHODS: We measured 15 phthalate, two di(2-ethylhexyl)terephthalate (DEHTP), and two di(isononyl)cyclohexane-1,2-dicarboxylate (DINCH) urinary metabolites, collected up to three times during pregnancy from 994 women in Northern Puerto Rico (2011-2017). We used tests of linear trend to assess changes in concentrations over time and linear mixed models to identify predictors of exposure (sociodemographic characteristics, drinking water sources, diet, product use). RESULTS: Several phthalate metabolites decreased over the study period indicating decreased exposure, while the geometric mean of DEHTP metabolites (molecular sum) increased threefold between 2014 and 2017. Intraclass correlations revealed low to moderate reproducibility of these biomarkers across pregnancy. Several metabolites were associated with maternal age, income, education, pre-pregnancy BMI, drinking public water, use of cleaning and personal care products, and ice cream consumption. DINCH metabolite concentrations remained low throughout the study period. CONCLUSION: Although exposure to some phthalates may be decreasing, exposure to replacements, such as DEHTP, is increasing. Additional studies are needed to further characterize sources of phthalate replacement chemicals and potential exposure-related health effects among vulnerable populations. |
Lessons of risk communication and health promotion - West Africa and United States
Bedrosian SR , Young CE , Smith LA , Cox JD , Manning C , Pechta L , Telfer JL , Gaines-McCollom M , Harben K , Holmes W , Lubell KM , McQuiston JH , Nordlund K , O'Connor J , Reynolds BS , Schindelar JA , Shelley G , Daniel KL . MMWR Suppl 2016 65 (3) 68-74 During the response to the 2014-2016 Ebola virus disease (Ebola) epidemic in West Africa, CDC addressed the disease on two fronts: in the epidemic epicenter of West Africa and at home in the United States. Different needs drove the demand for information in these two regions. The severity of the epidemic was reflected not only in lives lost but also in the amount of fear, misinformation, and stigma that it generated worldwide. CDC helped increase awareness, promoted actions to stop the spread of Ebola, and coordinated CDC communication efforts with multiple international and domestic partners. CDC, with input from partners, vastly increased the number of Ebola communication materials for groups with different needs, levels of health literacy, and cultural preferences. CDC deployed health communicators to West Africa to support ministries of health in developing and disseminating clear, science-based messages and promoting science-based behavioral interventions. Partnerships in West Africa with local radio, television, and cell phone businesses made possible the dissemination of messages appropriate for maximum effect. CDC and its partners communicated evolving science and risk in a culturally appropriate way to motivate persons to adapt their behavior and prevent infection with and spread of Ebola virus. Acknowledging what is and is not known is key to effective risk communication, and CDC worked with partners to integrate health promotion and behavioral and cultural knowledge into the response to increase awareness of the actual risk for Ebola and to promote protective actions and specific steps to stop its spread. The activities summarized in this report would not have been possible without collaboration with many U.S. and international partners (http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/partners.html). |
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.
Janssens AC , Ioannidis JP , Bedrosian S , Boffetta P , Dolan SM , Dowling N , Fortier I , Freedman AN , Grimshaw JM , Gulcher J , Gwinn M , Hlatky MA , Janes H , Kraft P , Melillo S , O'Donnell CJ , Pencina MJ , Ransohoff D , Schully SD , Seminara D , Winn DM , Wright CF , van Duijn CM , Little J , Khoury MJ . Eur J Epidemiol 2011 26 (4) 313-37 The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but they vary widely in completeness of reporting and apparent quality. Transparent reporting of the strengths and weaknesses of these studies is important to facilitate the accumulation of evidence on genetic risk prediction. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines. These recommendations aim to enhance the transparency, quality and completeness of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis. |
Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration.
Janssens AC , Ioannidis JP , Bedrosian S , Boffetta P , Dolan SM , Dowling N , Fortier I , Freedman AN , Grimshaw JM , Gulcher J , Gwinn M , Hlatky MA , Janes H , Kraft P , Melillo S , O'Donnell CJ , Pencina MJ , Ransohoff D , Schully SD , Seminara D , Winn DM , Wright CF , van Duijn CM , Little J , Khoury MJ . J Clin Epidemiol 2011 64 (8) e1-e22 The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but they vary widely in completeness of reporting and apparent quality. Transparent reporting of the strengths and weaknesses of these studies is important to facilitate the accumulation of evidence on genetic risk prediction. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines. These recommendations aim to enhance the transparency, quality and completeness of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis. |
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.
Janssens AC , Ioannidis JP , Bedrosian S , Boffetta P , Dolan SM , Dowling N , Fortier I , Freedman AN , Grimshaw JM , Gulcher J , Gwinn M , Hlatky MA , Janes H , Kraft P , Melillo S , O'Donnell CJ , Pencina MJ , Ransohoff D , Schully SD , Seminara D , Winn DM , Wright CF , van Duijn CM , Little J , Khoury MJ . Eur J Hum Genet 2011 19 (5) 18 p preceding 494 The rapid and continuing progress in gene discovery for complex diseases is fueling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but they vary widely in completeness of reporting and apparent quality. Transparent reporting of the strengths and weaknesses of these studies is important to facilitate the accumulation of evidence on genetic risk prediction. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by previous reporting guidelines. These recommendations aim to enhance the transparency, quality and completeness of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis. |
Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting.
Bellcross CA , Bedrosian SR , Daniels E , Duquette D , Hampel H , Jasperson K , Joseph DA , Kaye C , Lubin I , Meyer LJ , Reyes M , Scheuner MT , Schully SD , Senter L , Stewart SL , St Pierre J , Westman J , Wise P , Yang VW , Khoury MJ . Genet Med 2011 14 (1) 152-62 Lynch syndrome is the most common cause of inherited colorectal cancer, accounting for approximately 3% of all colorectal cancer cases in the United States. In 2009, an evidence-based review process conducted by the independent Evaluation of Genomic Applications in Practice and Prevention Working Group resulted in a recommendation to offer genetic testing for Lynch syndrome to all individuals with newly diagnosed colorectal cancer, with the intent of reducing morbidity and mortality in family members. To explore issues surrounding implementation of this recommendation, the Centers for Disease Control and Prevention convened a multidisciplinary working group meeting in September 2010. This article reviews background information regarding screening for Lynch syndrome and summarizes existing clinical paradigms, potential implementation strategies, and conclusions, which emerged from the meeting. It was recognized that wide-spread implementation will present substantial challenges, and additional data from pilot studies will be needed. However, evidence of feasibility and population health benefits and the advantages of considering a public health approach were acknowledged. Lynch syndrome can potentially serve as a model to facilitate the development and implementation of population-level programs for evidencebased genomic medicine applications involving follow-up testing of at-risk relatives. Such endeavors will require multilevel and multidisciplinary approaches building on collaborative public health and clinical partnerships. |
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.
Janssens AC , Ioannidis JP , Bedrosian S , Boffetta P , Dolan SM , Dowling N , Fortier I , Freedman AN , Grimshaw JM , Gulcher J , Gwinn M , Hlatky MA , Janes H , Kraft P , Melillo S , O'Donnell CJ , Pencina MJ , Ransohoff D , Schully SD , Seminara D , Winn DM , Wright CF , van Duijn CM , Little J , Khoury MJ . Eur J Clin Invest 2011 41 (9) 1010-35 SUMMARY POINTS: *The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application of genetic risk models for clinical and public health practice. *The number of studies assessing the predictive ability is steadily increasing, but they vary widely in completeness of reporting and apparent quality. *Transparent reporting of the strengths and weaknesses of these studies is important to facilitate the accumulation of evidence on genetic risk prediction. *A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines. *These recommendations aim to enhance the transparency, quality and completeness of study reporting and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 20, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure